bioRxivMolecular BiologyPreprint
Decreased miRNA-148a-3p expression in skeletal muscle of patients with chronic kidney disease
KA Robinson, LA Baker, Matthew P. M. Graham-BrowniD, RU Ashford, Izabella Pawlyckz, Rupert MajoriD, James O. BurtoniD, Nicolas B. SylviusiD, A Cooper, Ashleigh M. PhilpiD, EL WatsoniD
Abstract
IntroductionSkeletal muscle wasting is a common complication of chronic kidney disease which leads to a loss of muscle function. The pathogenesis of skeletal muscle wasting is incompletely understood, which is preventing the development of targeted therapeutics. Recent evidence implicates miRNAs in the of skeletal muscle wasting. Our aim was to firstly examine miRNA profiles of CKD human skeletal muscle for the identification of aberrant expression patterns compared to a healthy control (HC) cohort, and secondly, investigate the role these miRNAs may play in inducing or promoting skeletal muscle atrophy using a novel human primary skeletal muscle cell model of CKD skeletal muscle. MethodsFor the comparison between CKD and HC populations, skeletal muscle biopsies were collected from the vastus lateralis of n=15 non-dialysis dependent CKD patients stage 3b-5 CKD patients, and n=15 healthy controls matched for age, gender and physical activity. n=5 biopsies from each group underwent next generation sequencing to obtain complete microRNA profiles in CKD vs HC cohorts, which were then validated in a separate cohort by PCR (N=10 in each group). A causative role in muscle wasting was determined by transfection of key microRNAs into a primary culture model of CKD skeletal muscle and changes in protein degradation determined by L-[3H]- phenylalanine release into the media. ResultsNext Generation Sequencing identified differential expression of 16 miRNAs in skeletal muscle of CKD patients versus controls, and PCR validation confirmed miRNA-148a-3p expression was significantly decreased in CKD patients. The reduced miRNA-148a-3p expression was also maintained in the primary culture model. Upon overexpression of miRNA-148a-3p in CKD myotubes, protein degradation rates were decreased non-significantly (p=0.28) by 16.3% compared to un-transfected CKD cells. ConclusionCKD was associated with a significant reduction in miRNA-148a-3p expression in skeletal muscle compared to non-CKD controls which was retained in our in vitro model. Overexpression of miRNA-148a-3p in primary skeletal myotubes non-significantly decreased muscle protein degradation by 16.3%. In order to determine the importance of miRNA-148a-regulation of protein degradation, a deeper understanding of miRNA-148a-3p targets and their associated pathways with respect to those dysregulated in skeletal muscle wasting is required.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Establishment and characterisation of primary skeletal muscle cell cultures from patients with advanced Chronic Kidney Disease
L. A. Baker, T. F. O'Sullivan, … E. L. Watson·bioRxiv·Nov 16, 2020
- Transcriptomic Suppression of Immune and Regenerative Signalling in Skeletal Muscle of Patients with Chronic Kidney Disease
Luke A. Baker, Nicholas C. Eastley, … Emma L Watson·bioRxiv·Jul 11, 2025
- ROCK1 activates mitochondrial fission leading to oxidative stress and muscle atrophy
- Anabolic and catabolic responses to different modes of exercise in patients with chronic kidney disease
Doug William Gould, Luke A. Baker, … Emma L Watson·BMC NephrologyPeer-reviewed·Mar 13, 2026
- The response of the skeletal muscle transcriptome to exercise in chronic kidney disease
Luke A. Baker, Matthew P. M. Graham-Brown, … Emma L Watson·bioRxiv·Apr 25, 2025
- Identification of the Col4a3-/- mouse as a model of chronic kidney disease-associated cachexia
Marie Buléon, Manon Brunet, … Pauline Morigny·bioRxiv·Oct 12, 2026